Retension Pharmaceuticals

Executive Summary

Retension Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, MA, focused on developing novel small molecule therapies for hypertension and cardiovascular diseases. Founded in 2018, the company's lead candidate, RTN-001, is a tissue-targeted PDE5 inhibitor designed to address uncontrolled hypertension, a condition affecting millions worldwide. By selectively targeting PDE5 in vascular tissues, RTN-001 aims to improve efficacy while reducing systemic side effects commonly associated with other PDE5 inhibitors. The company is currently advancing RTN-001 through clinical development, with potential to offer a new treatment option for patients with resistant or uncontrolled hypertension. Despite being in early clinical stages, Retension's differentiated approach leverages established PDE5 biology with innovative tissue targeting, positioning it as a promising player in the cardiovascular space. The private company has not disclosed funding rounds or valuation, indicating a lean operation or early investment phase. Key milestones over the next 12–24 months will be critical to validate RTN-001's safety and efficacy profile, potentially attracting partnership interest or additional financing.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 top-line data for RTN-001 in uncontrolled hypertension40% success
• Q4 2026Initiation or update of a second pipeline program (preclinical or IND)30% success
• Q3 2026Strategic partnership or licensing deal for RTN-00120% success